Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1717340 | 0.86 | CCR1 (0.53) | CISD1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL22678920 | 0.79 | KDM4E (0.48) | CISD1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL13266184 | 0.79 | KDM4E (0.48) | CISD1KDM4EMAPTMEN1KMT2A | |
| Quinoline SCHEMBL29291034 | 0.78 | ALDH1A1 (0.57) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL194281 | 0.75 | KDM4E (0.54) | KDM4EMAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL28282372 | 0.75 | KDM4E (0.54) | CISD1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL16307974 | 0.75 | KDM4E (0.44) | CISD1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL31028400 | 0.75 | KDM4E (0.51) | CISD1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL1071836 | 0.73 | KDM4E (0.58) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL27822917 | 0.73 | KDM4E (0.52) | KDM4EMAPTMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-118530187-A | Diazonium compound for detecting phosphorylated small molecules, preparation method and application thereof | 国科大杭州高等研究院 | 2024-08-23 | — | — | CN | claimed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | claimed |
| EP-3856179-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2021-08-04 | — | — | EP | claimed |
| CN-113164459-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | claimed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4573086-A1 | METHANOGEN INHIBITORS | Agrizeronz Limited Partnership (NZ) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998272-A | Methanogen inhibitors | 阿格里泽伦茨有限合伙公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024216094-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| US-4621082-A | Pyridopyrimidines, pharmaceutical compositions and use | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-04 | — | — | US | disclosed |
| EP-0189045-A2 | Pyridopyrimidines, different processes for their preparation as well as their use as medicaments | BAYER AG (DE) | 1986-07-30 | — | — | EP | disclosed |
| EP-0088276-B1 | COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PREPARATIONS | BAYER AG (DE) | 1986-04-30 | — | — | EP | disclosed |
| US-4565824-A | Certain nitratoalkyl ester dihydropyridines having antihypertensive properties | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-21 | — | — | US | disclosed |
| EP-0110259-A1 | 1,4-Dihydropyridines, processes for their preparation and their use in medicines | BAYER AG (DE) | 1984-06-13 | — | — | EP | disclosed |
| EP-0088276-A1 | Compounds, process for their preparation and their use as pharmaceutical preparations | BAYER AG (DE) | 1983-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | CISD1 1331/4885KDM4E 3565/4885MAPT 3782/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CISD1 3274/4885KDM4E 2800/4885MAPT 2188/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CISD1 3274/4885KDM4E 2800/4885MAPT 2188/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CISD1 3274/4885KDM4E 2800/4885MAPT 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.